Elevated plasma monounsaturated fatty acids and their associations with disease activity, adiposity and sex in patients with rheumatoid arthritis: a cross-sectional study Authors: Shalini Narayana Swamy, Martha A Belury, Rachel M Cole, Kristen Heitman, Steven Pan, Zhibo Yang, Aizhan Karabukayeva, Yang Mao-Draayer, Beatriz Yae Hanaoka Published: 2026 ABSTRACT AbstractBackgroundRheumatoid arthritis (RA) is a chronic autoimmune disease associated with systemic inflammation and metabolic alterations that may influence circulating lipid profiles. While polyunsaturated fatty acids have been widely studied, less is known about monounsaturated fatty acids (MUFAs), their endogenous synthesis and their relationships with disease activity and adiposity.MethodsIn this cross-sectional study, 52 individuals with RA and 30 matched controls were recruited (2017–2022). Disease activity (Disease Activity Score in 28 joints-C reactive protein (DAS28-CRP)), body composition and metabolic parameters were assessed. Dietary intake was captured using a 4-day food journal. Plasma fatty acids were measured by gas chromatography and the stearoyl-CoA desaturase-1 (SCD-1) index estimated endogenous MUFA synthesis. Multivariable regression with false discovery rate correction was used.ResultsParticipants with RA had lower insulin sensitivity, higher triglycerides and lower physical activity levels. Plasma oleic and palmitoleic acids and the SCD-1 index were higher in RA, while linoleic and arachidonic acids were lower; saturated and omega-3 fatty acids did not differ. After adjustment for age, sex and diet, oleic acid was associated with RA status (β=1.4; 95% CI 0.33 to 2.5) and waist-to-hip ratio (β=14; 95% CI 6.9 to 21). Among participants with RA, higher oleic acid and gondoic acid were associated with DAS28-CRP, while palmitoleic acid was higher in women but not associated with DAS28-CRP.ConclusionsCirculating MUFAs are associated with RA status, adiposity and disease activity after adjusting for diet, supporting a role for endogenous lipid metabolism in RA. WHAT IS ALREADY KNOWN ON THIS TOPIC RA is associated with systemic inflammation and altered lipid metabolism. RA is associated with systemic inflammation and altered lipid metabolism. While polyunsaturated fatty acids have been extensively studied in RA, less is known about the plasma levels and clinical relevance of MUFAs. While polyunsaturated fatty acids have been extensively studied in RA, less is known about the plasma levels and clinical relevance of MUFAs. WHAT THIS STUDY ADDS This study demonstrates selective alterations in circulating MUFAs in RA. This study demonstrates selective alterations in circulating MUFAs in RA. Oleic acid was consistently associated with disease activity and adiposity after accounting for reported dietary intake, while other MUFAs showed more limited or distinct associations. Oleic acid was consistently associated with disease activity and adiposity after accounting for reported dietary intake, while other MUFAs showed more limited or distinct associations. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Circulating MUFAs, particularly oleic acid, may reflect disease activity and metabolic dysregulation. Circulating MUFAs, particularly oleic acid, may reflect disease activity and metabolic dysregulation. These findings highlight endogenous lipid metabolism as a potential link between adiposity and inflammation, supporting further investigation into metabolic pathways as therapeutic targets. These findings highlight endogenous lipid metabolism as a potential link between adiposity and inflammation, supporting further investigation into metabolic pathways as therapeutic targets. Introduction Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by chronic synovial inflammation and associated metabolic dysfunction.1 Its pathogenesis involves a complex interplay of genetic, environmental and immunological factors that promote aberrant immune activation and persistent inflammation.2 Alterations in plasma fatty acid composition have been linked to immune dysregulation in RA and other diseases.3 Polyunsaturated fatty acids (PUFAs) are among the most extensively studied fatty acids in RA. N-6 fatty acids, such as arachidonic acid, serve as precursors for both pro-inflammatory eicosanoids (eg, prostaglandins and leukotrienes), whereas n-3 fatty acids generate anti-inflammatory and pro-resolving mediators.4 5 Observational data suggest that a higher dietary n-6 to n-3 PUFA intake ratio may be associated with greater pain in early RA despite well-controlled inflammation.6 Conversely, supplementation with n-3-rich fish oil in patients with RA has been associated with modest improvements in clinical outcomes, including reductions in tender joint counts and non-steroidal anti-inflammatory drug use, in randomised trials and meta-analyses.7 8 Beyond PUFAs, other fatty acids may also influence immune and metabolic pathways. Among monounsaturated fatty acids (MUFAs), oleic acid (18:1n9) has demonstrated anti-inflammatory effects in experimental studies and may exert similar anti-inflammatory effects in humans.9 Oleic acid (18:1n9) and palmitoleic acid (16:1n7) are the most abundant MUFAs in humans and arise from both dietary intake and endogenous metabolism.10 Chronic inflammatory conditions such as RA may alter lipid metabolism through inflammatory cytokines, insulin resistance and changes in adipose tissue function, potentially influencing endogenous MUFA synthesis. When dietary intake is limited or metabolic demand is increased, endogenous MUFA synthesis contributes substantially to circulating MUFA levels. This process is regulated by stearoyl-CoA desaturase-1 (SCD-1), the rate-limiting enzyme that converts saturated fatty acids, stearic (18:0) and palmitic (16:0) acids, into oleic and palmitoleic acids.11 The oleic-to-stearic acid ratio (18:1/18:0) is commonly used as a surrogate marker of SCD-1 activity, providing an indirect measure of endogenous MUFA production.12 13 SCD-1 is tightly regulated by multiple physiological and environmental factors. Dietary components, including PUFAs and carbohydrates, as well as hormonal signals such as insulin, play a key role in controlling its activity.11 PUFAs generally suppress SCD-1,14 whereas carbohydrates and insulin stimulate SCD-1 activity,15 promoting endogenous MUFA synthesis. By modulating MUFA availability, these dietary and hormonal factors may influence metabolic pathways that are linked to systemic inflammation.11 While PUFAs have been extensively studied in RA, less is known about circulating MUFAs and their relationship to disease activity and adiposity. Therefore, the objective of this study was to compare plasma MUFA profiles in patients with RA and matched controls and to examine their associations with disease activity, adiposity and dietary intake. We hypothesised that RA would be associated with altered circulating MUFA levels and SCD-1 activity estimated by the SCD-1 index, and that these measures would relate to disease activity and adiposity. Methods Study aim, design and setting This cross-sectional study aimed to investigate plasma MUFAs in patients with RA compared with matched controls and to examine their associations with disease activity, body composition and endogenous metabolic regulation. Participants were recruited from rheumatology outpatient clinics at participating institutions between March 2017 and June 2022, including the University of Alabama at Birmingham, the Ohio State University and the University of Oklahoma Health Sciences Center. Recruitment occurred across sites using the same study protocol, and standardised operating procedures were used for sample collection, processing and storage to ensure consistency across study sites. Participants Participants with RA were recruited from rheumatology outpatient clinics at participating institutions and non-RA controls were recruited from community volunteers. Participants with RA met the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA.16 Consistent with this cohort’s prior description,17 eligible participants were adults aged 35–65 years; control participants were frequency matched to participants with RA on age, sex and body mass index (BMI). Participants were excluded if they had type 2 diabetes mellitus, a history of resistance training, other autoimmune or chronic inflammatory diseases, chronic viral infection, chronic liver or kidney disease or pregnancy. Control participants were additionally screened to exclude inflammatory arthritis and autoimmune disease. Participants included in the present analysis were those with available plasma fatty acid measurements and dietary assessment data. Clinical assessments For patients with RA, disease duration and current medication use were recorded, including prednisone and disease-modifying antirheumatic drugs (DMARDs), encompassing conventional synthetic, biologic and targeted synthetic agents. Rheumatoid factor and anticyclic citrullinated peptide antibodies were measured in the clinical laboratory. Disease activity was assessed using the Disease Activity Score in 28 joints C-reactive protein (DAS28-CRP). Metabolic parameters, including haemoglobin A1c (HbA1c), fasting triglycerides and insulin sensitivity estimated by the Matsuda Index18 from a 2-hour oral glucose tolerance test, were also measured to characterise the metabolic profile of study participants. Anthropometric measurements Height, weight, waist and hip circumferences were obtained in accordance with National Health and Nutrition Examination Survey III anthropometric measurement protocol.19 BMI was calculated as weight (kg) divided by height squared (m²). Waist-to-hip ratio (WHR) was calculated as waist circumference divided by hip circumference. Whole-body dual-energy X-ray absorptiometry (DEXA) was used to assess body composition, from which fat mass index (fat mass (kg)/height² (m²)) and fat-free mass index (fat-free mass (kg)/height² (m²)) were derived. Plasma fatty acid analysis Plasma total lipids were extracted according to the method by Folch et al.20 Fatty acid methyl esters (FAMEs) were prepared using 5% hydrochloric acid in methanol.21 Gas chromatography analysis of FAMEs was conducted using a 30 m Omegawax 320 fused silica capillary column (Supelco, Bellefonte, Pennsylvania, USA). Retention times of samples were compared with FAME standards (Matreya, Pleasant Gap, Pennsylvania, USA and Nu-Check Prep, Elysian, Minnesota, USA). Individual fatty acids were expressed as a percentage of total identified fatty acids, a commonly used approach for characterising plasma fatty acid composition in epidemiological and metabolic studies.22 SCD-1 activity was estimated indirectly using the plasma ratio of oleic-to-stearic acid (18:1n9/18:0), a commonly used proxy for SCD-1 activity.13 Physical activity assessment Physical activity was assessed using the short form of the International Physical Activity Questionnaire (IPAQ)23 to characterise participants’ lifestyle behaviours. Total activity was expressed in metabolic equivalent of task (MET)-minutes per week, calculated according to the IPAQ scoring protocol as the sum of walking, moderate and vigorous activity. Dietary assessment Dietary intake data were collected using a 4-day self-reported food journal, which was analysed with the Nutrition Data System for Research software V.2016 (Nutrition Coordinating Center, University of Minnesota, Minneapolis, Minnesota, USA) to characterise participants’ dietary patterns and quantify intake of fatty acids.24 Diet quality was assessed using the Healthy Eating Index-2015 (HEI-2015), which compares participant dietary intake with the Dietary Guidelines for Americans. The energy-adjusted HEI-2015 was calculated using a density-based, energy-adjusted scoring approach (per 1000 kcal) in accordance with established methodology.25 Statistical analysis Continuous variables are presented as mean±SD or median (IQR), as appropriate, and categorical variables as counts and percentages. Differences between patients with RA and non-RA controls were assessed using Student’s t-test or Wilcoxon rank-sum test for continuous variables and χ2 test or Fisher’s exact test for categorical variables. Associations between plasma MUFAs and RA disease activity, measured by DAS28-CRP, were evaluated among participants with RA using Spearman’s correlation. Multivariable linear regression models were constructed to assess the independent associations of individual MUFAs with RA disease activity (DAS28-CRP) and, separately, with RA status (RA vs control), adjusting for age, sex, dietary intake of the specific fatty acid and WHR. Regression model assumptions, including linearity, normality of residuals and homoscedasticity, were examined and met. Sample size was determined by the number of participants enrolled during the recruitment period with available plasma fatty acid measurements and dietary intake data; no a priori power calculation was performed. Multivariable analyses were performed using the full analytic dataset, as there were no missing values for variables included in the models; thus, sample sizes were consistent across analyses. Multivariable linear regression models were constructed to assess associations of individual fatty acids with RA status and, separately, with RA disease activity (DAS28-CRP), adjusting for age, sex, WHR and reported dietary intake of the corresponding fatty acid. All statistical analyses were conducted using R software (V.4.4.0). Statistical significance was defined as a two-sided false discovery rate (FDR)-adjusted p value (q value) <0.05 for analyses subject to multiple testing. Bias To reduce confounding, non-RA controls were matched to participants with RA on age, sex and BMI, and multivariable regression models further adjusted for age, sex, WHR and dietary intake of the corresponding fatty acid. Standardised protocols were used across study sites for anthropometric measurements, DEXA and disease activity assessment (DAS28-CRP). Dietary intake was assessed using a 4-day self-reported food journal, which may be subject to recall and reporting error. Plasma fatty acids were quantified using standardised gas chromatography methods and laboratory personnel performing fatty acid analyses were blinded to participant RA status. Results We first compared demographic, metabolic and plasma fatty acid profiles between participants with RA and matched controls. We then examined dietary fatty acid intake to determine whether differences in circulating fatty acids could be explained by diet. Finally, we evaluated associations between plasma fatty acids and clinical parameters, including disease activity and adiposity, using correlation and multivariable regression analyses. Participant characteristics A total of 52 patients with RA and 30 controls frequency-matched on age, sex and BMI were included in the analysis (table 1). Participants with RA had a median age of 56 years (IQR 50–61), were predominantly women (87%) and had a median BMI of 30 kg/m² (IQR 26–35). Matching variables did not differ significantly between groups (all p>0.20). Compared with controls, patients with RA had lower insulin sensitivity as assessed by the Matsuda Index (3.43 vs 4.99, p=0.031), higher fasting triglycerides (94 vs 71 mg/dL, p=0.010) and lower physical activity (2354 vs 4305 MET-min/week, p=0.031). These findings reflect a less favourable metabolic profile and lower physical activity levels in RA compared with controls. Lipid-lowering therapy was reported by eight participants with RA (15%) and two controls (6.7%) (p=0.31). Among participants with RA (table 2), 67% were seropositive, with a median disease duration of 7 years and a median DAS28-CRP of 1.5. Prednisone use was low (15%, median dose of 5 mg/day) and 86% were on DMARDs. Table 1Demographic, clinical and dietary characteristics of study participants by RA status (n=82)CharacteristicControl (n=30)*RA (n=52)*P value†Age (years)53 (43, 59)56 (50, 61)0.2Sex, female, n (%)27 (90%)45 (87%)0.7BMI, (kg/m2)†28 (25, 32)30 (26, 35)0.3Waist-to-hip ratio0.87 (0.82, 0.92)0.89 (0.85, 0.93)0.073FFMI (kg/m2)†16.22 (14.97, 18.55)16.73 (15.66, 18.12)0.5FMI (kg/m2)†11.2 (7.8, 12.7)12.9 (9.9, 18.0)0.059Energy-adjusted HEI-2015 score−0.33 (−0.75, 1.09)−0.10 (−0.97, 0.85)0.9Matsuda Index4.99 (3.61, 6.83)3.43 (2.26, 5.70) 0.031 HbA1c (%)5.40 (5.20, 5.70)5.40 (5.20, 5.70)0.8HDL (mg/dL)73 (60, 85)61 (55, 74)0.069Triglycerides (mg/dL)71 (51, 94)94 (68, 163) 0.010 Total METs (MET-min/week)4305 (2100, 14 130)2354 (1094, 7016) 0.031 Bolded values indicate statistical significance (p < 0.05).*Median (Q1, Q3); n (%).†Wilcoxon rank-sum test; Fisher’s exact test.BMI, body mass index; FFMI, fat-free mass index; FMI, fat mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein cholesterol; HEI, Healthy Eating Index; METs, metabolic equivalents of task; RA, rheumatoid arthritis. Demographic, clinical and dietary characteristics of study participants by RA status (n=82) Bolded values indicate statistical significance (p < 0.05). Median (Q1, Q3); n (%). Wilcoxon rank-sum test; Fisher’s exact test. BMI, body mass index; FFMI, fat-free mass index; FMI, fat mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein cholesterol; HEI, Healthy Eating Index; METs, metabolic equivalents of task; RA, rheumatoid arthritis. Table 2Clinical characteristics of participants with RA (n=52)CharacteristicRA (n=52)*RF positive31 (67%)Anti-CCP positive30 (64%)RF or anti-CCP positive36 (77%)Disease duration (years)7 (4, 14)DAS28-CRP1.5 (0.7, 5.9)Prednisone use Current7 (15%) Past34 (74%) Never5 (11%)Current prednisone dose (mg/day)5 (4, 5)Any current DMARD use44 (86%) Methotrexate22 (43%) Hydroxychloroquine14 (27%) Sulfasalazine2 (3.9%) Etanercept5 (9.6%) Adalimumab11 (21%) Infliximab1 (1.9%) Abatacept4 (7.8%) Rituximab2 (3.8%) Tocilizumab2 (3.8%) Tofacitinib3 (5.9%)Prednisone use data were unavailable for 6 participants.*N (%); median (Q1, Q3).anti-CCP, anticyclic citrullinated peptide; DAS28-CRP, Disease Activity Score in 28 joints using C-reactive protein; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor. Clinical characteristics of participants with RA (n=52) Prednisone use data were unavailable for 6 participants. N (%); median (Q1, Q3). anti-CCP, anticyclic citrullinated peptide; DAS28-CRP, Disease Activity Score in 28 joints using C-reactive protein; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor. Plasma fatty acid profiles Plasma MUFAs (figure 1A) were elevated in patients with RA, including palmitoleic acid (1.93% (IQR 1.36–2.74) vs 1.46% (IQR 1.17–2.14), p=0.022) and oleic acid (18.73% (IQR 17.18–20.42) vs 16.87% (IQR 14.91–18.19), p=0.001), alongside higher SCD-1 index (2.67 (IQR 2.38–2.93) vs 2.21 (IQR 1.93–2.79), p=0.010). In contrast, n-6 PUFAs (figure 1B), including linoleic acid (31.59% (IQR 28.89–33.33) vs 33.03% (IQR 30.86–35.67), p=0.035) and arachidonic acid (7.28% (IQR 6.43–8.21) vs 8.51% (IQR 7.19–9.67), p=0.004), were lower in RA, which may reflect altered metabolic utilisation in inflammatory or oxidative pathways. No significant differences were observed in saturated fatty acids (figure 1C) or n-3 PUFAs (figure 1D), suggesting that changes in fatty acid composition may be limited to specific lipid classes. Plasma fatty acid composition by rheumatoid arthritis (RA) status. (A) Monounsaturated fatty acids (MUFAs), (B) polyunsaturated omega-6 fatty acids (PUFA n-6), (C) saturated fatty acids and (D) polyunsaturated omega-3 fatty acids (PUFA n-3) are shown as percentage of total plasma fatty acids in participants with RA (n=52) and non-RA controls (n=30). Individual data points represent participants; black dots indicate group means with error bars representing SD. Comparisons between RA and control groups were performed using Welch’s two-sample t-test or Wilcoxon rank-sum test, as appropriate based on data distribution. Significance is indicated as *p<0.05 and **p<0.01. These analyses are presented for descriptive purposes; no adjustment for multiple comparisons was applied. Fatty acids are labelled by common name and carbon chain designation (eg, C18:1n9). Dietary intake Overall diet quality, assessed by the energy-adjusted HEI-2015 score, was comparable between individuals with RA and controls (p=0.9) (table 1). There were no significant differences in average dietary intake (online supplemental table 1) of palmitoleic, oleic, gondoic, linoleic or arachidonic acids between patients with RA and controls (all p>0.5). These findings suggest that the observed differences in plasma fatty acids were not fully explained by measured dietary intake. Correlations with clinical parameters Spearman’s correlation analyses (online supplemental table 2) were performed separately in participants with RA and non-RA controls. To account for multiple comparisons, nominal p values were adjusted using the Benjamini-Hochberg FDR procedure and significance was interpreted based on q values. Among participants with RA, several associations remained significant after FDR correction. Higher oleic acid was positively correlated with DAS28-CRP (ρ=0.450, q=0.008) and WHR (ρ=0.454, q=0.007). Higher palmitoleic acid was positively correlated with fat mass index (ρ=0.434, q=0.013) and inversely associated with the Matsuda Index (ρ=−0.400, q=0.026). Higher linoleic acid was positively correlated with the Matsuda Index (ρ=0.455, q=0.007). Higher gondoic acid was positively correlated with DAS28-CRP (ρ=0.428, q=0.013) and inversely correlated with HbA1c (ρ=−0.412, p=0.004, q=0.028). Several additional RA correlations were nominally significant but did not remain significant after FDR correction, including palmitoleic acid with BMI, DAS28-CRP and HEI 2015 score; oleic acid with CRP and Matsuda Index and linoleic acid with DAS28-CRP and WHR. Among non-RA controls, palmitoleic acid was positively correlated with CRP (ρ=0.592, q=0.008), linoleic acid was inversely correlated with WHR (ρ=−0.580, q=0.012) and gondoic acid was inversely correlated with total METs (ρ=−0.506, q=0.043). No correlations involving arachidonic acid remained significant after FDR correction in either group. Multivariable analyses In multivariable analyses of the overall cohort, MUFAs, particularly oleic acid (table 3) and palmitoleic acid (table 4), were associated with RA status and WHR after adjustment for age, sex and corresponding dietary intake. Higher oleic acid level was associated with RA status (β=1.4; 95% CI 0.33 to 2.5; q=0.028) and with higher WHR (β=14; 95% CI 6.9 to 21; q<0.001). Similarly, higher palmitoleic acid was associated with RA status (RA: β=0.41; 95% CI 0.05 to 0.77; q=0.042), higher WHR: β=3.4; 95% CI 1.1 to 5.8; q=0.011) and female sex (β=0.91; 95% CI 0.35 to 1.5; q=0.009). Age and reported dietary intake were not significantly associated with oleic or palmitoleic acid in adjusted models. Gondoic acid was not associated with RA status or WHR in the overall cohort (all q≥0.62) (online supplemental table 3). Table 3Multivariable associations of plasma oleic acid (C18:1n9) with demographic, dietary, adiposity and disease activity measures by RA status (overall cohort, n=82)CharacteristicUnivariateMultivariateCoef (95% CI)q valueCoef (95% CI)q valueAge0.06 (−0.01 to 0.12)0.170.05 (−0.02 to 0.11)0.20Sex, female0.21 (−1.5 to 2.0)0.811.5 (−0.19 to 3.2)0.13Average dietary intake of oleic acid0.02 (−0.02 to 0.05)0.400.01 (−0.02 to 0.04)0.55RA status (reference: control) RA1.8 (0.71 to 2.9) 0.004 1.4 (0.33 to 2.5) 0.028 Waist-to-hip ratio15 (7.9 to 21) <0.001 14 (6.9 to 21)<0.001Coefficients represent β estimates from linear regression models. Multivariable models were adjusted for age, sex and average dietary intake of oleic acid. The q values represent false discovery rate-adjusted p values. Statistically significant associations (q<0.05) are shown in bold. Continuous variables were modelled per unit increase. Reference category for RA status is non-RA controls.RA, rheumatoid arthritis. Multivariable associations of plasma oleic acid (C18:1n9) with demographic, dietary, adiposity and disease activity measures by RA status (overall cohort, n=82) Coefficients represent β estimates from linear regression models. Multivariable models were adjusted for age, sex and average dietary intake of oleic acid. The q values represent false discovery rate-adjusted p values. Statistically significant associations (q<0.05) are shown in bold. Continuous variables were modelled per unit increase. Reference category for RA status is non-RA controls. RA, rheumatoid arthritis. Table 4Multivariable associations of plasma palmitoleic acid (C16:1n7) with demographic, dietary, adiposity and disease activity measures by RA status (overall cohort, n=82)CharacteristicUnivariateMultivariateCoef (95% CI)q valueCoef (95% CI)q valueAge−0.01 (−0.03 to 0.01)0.470.00 (−0.03 to 0.02)0.81Sex, female0.76 (0.24 to 1.3) 0.022 0.91 (0.35 to 1.5) 0.009 Average dietary intake of palmitoleic acid−0.10 (−0.37 to 0.17)0.47−0.03 (−0.30 to 0.23)0.81RA status (reference: control) RA0.46 (0.10 to 0.82) 0.022 0.41 (0.05 to 0.77) 0.042 Waist-to-hip ratio3.0 (0.76 to 5.3) 0.022 3.4 (1.1 to 5.8) 0.011 Coefficients represent β estimates from linear regression models. Multivariable models were adjusted for age, sex and average dietary intake of palmitoleic acid. The q values represent false discovery rate-adjusted p values. Statistically significant associations (q<0.05) are shown in bold. Continuous variables were modelled per unit increase. Reference category for RA status is non-RA controls.RA, rheumatoid arthritis. Multivariable associations of plasma palmitoleic acid (C16:1n7) with demographic, dietary, adiposity and disease activity measures by RA status (overall cohort, n=82) Coefficients represent β estimates from linear regression models. Multivariable models were adjusted for age, sex and average dietary intake of palmitoleic acid. The q values represent false discovery rate-adjusted p values. Statistically significant associations (q<0.05) are shown in bold. Continuous variables were modelled per unit increase. Reference category for RA status is non-RA controls. RA, rheumatoid arthritis. In contrast, linoleic acid was not associated with RA status in the adjusted model (β=−1.10, 95% CI −2.78 to 0.57; q=0.24), but it was inversely associated with WHR (β=−23.2; 95% CI −34.0 to −12.4; q<0.001) and was lower in females (β=−3.83; 95% CI −6.42 to −1.25; q=0.010) (table 5). Arachidonic acid showed no significant associations with RA status, adiposity or other covariates after FDR corrections (all q≥0.084) (online supplemental table 4). Table 5Multivariable associations of plasma linoleic acid (C18:2n6) with demographic, dietary, adiposity and disease activity measures by RA status (overall cohort, n=82)CharacteristicUnivariateMultivariateCoef (95% CI)q valueCoef (95% CI)q valueAge−0.0555 (−0.1591 to 0.0481)0.36−0.0679 (−0.1673 to 0.0315)0.24Sex, female−1.7942 (−4.3818 to 0.7933)0.29−3.8346 (−6.4190 to 1.2502) 0.010 Average dietary intake of linoleic acid−0.0090 (−0.1005 to 0.0825)0.84−0.0182 (−0.1030 to 0.0667)0.67RA status (reference: control) RA−1.7935 (−3.5268 to −0.0601)0.11−1.1047 (−2.7773 to 0.5679)0.24Waist-to-hip ratio−19.739 (−30.017 to −9.4620) 0.001 −23.162 (−33.967 to −12.356) <0.001 Coefficients represent β estimates from linear regression models. Multivariable models were adjusted for age, sex and average dietary intake of linoleic acid. The q values represent false discovery rate-adjusted p values. Statistically significant associations (q<0.05) are shown in bold. Continuous variables were modelled per unit increase. Reference category for RA status is non-RA controls.RA, rheumatoid arthritis. Multivariable associations of plasma linoleic acid (C18:2n6) with demographic, dietary, adiposity and disease activity measures by RA status (overall cohort, n=82) Coefficients represent β estimates from linear regression models. Multivariable models were adjusted for age, sex and average dietary intake of linoleic acid. The q values represent false discovery rate-adjusted p values. Statistically significant associations (q<0.05) are shown in bold. Continuous variables were modelled per unit increase. Reference category for RA status is non-RA controls. RA, rheumatoid arthritis. Among patients with RA, higher oleic acid levels were associated with greater disease activity (DAS28-CRP), such that each 1% higher oleic acid was associated with a 0.65-point higher DAS28-CRP (95% CI 0.11 to 1.2; q=0.048) and with higher WHR (β=13; 95% CI 4.5 to 21; q=0.015) (online supplemental table 5). Higher plasma gondoic acid was also associated with greater DAS28-CRP (β=0.0108; 95% CI 0.0043 to 0.0173; q=0.009), but was not associated with WHR (q=0.97) (online supplemental table 6). In contrast, palmitoleic and linoleic acids were not associated with DAS28-CRP or adiposity measures in multivariable analyses (online supplemental tables 7 and 8). Discussion This study demonstrates altered plasma MUFA profiles in RA, with higher circulating oleic acid levels consistently associated with both disease activity and adiposity. These associations persisted after adjusting for reported dietary intake, suggesting that factors beyond dietary exposure, including endogenous metabolic regulation, may contribute to the observed lipid differences, although causality cannot be inferred from this cross-sectional analysis. In contrast, not all MUFAs showed consistent associations: while gondoic acid was associated with disease activity in RA-only analyses, it was not associated with adiposity or with RA status in the overall cohort, and palmitoleic acid was not associated with disease activity. These findings support selective, rather than global, alterations in MUFA metabolism in RA, with specific fatty acids linking adiposity and disease activity. RA is characterised by persistent synovial inflammation driven by complex interactions between innate and adaptive immune pathways, including activation of macrophages, T cells and fibroblast-like synoviocytes and the production of pro-inflammatory cytokines such as tumour necrosis factor-α, interleukin (IL)-6 and IL-1β. Lipid mediators derived from fatty acids play an important role in regulating these inflammatory pathways, and lipidomic studies have demonstrated substantial alterations in lipid profiles associated with disease activity in RA.26 In this context, changes in circulating MUFAs and PUFA profiles may reflect systemic metabolic responses to chronic inflammation rather than direct dietary effects. The SCD-1 index, reflected by the oleic-to-stearic acid ratio, was higher in participants with RA and is commonly used as a surrogate marker of endogenous MUFA synthesis. However, this index reflects systemic lipid metabolism and does not directly measure tissue-specific enzyme activity. SCD-1 is highly expressed in the liver and adipose tissues, which contribute substantially to circulating MUFA levels.27 It is also present in immune cells, including macrophages, T cells, dendritic cells and B cells, where expression can increase during activation and proliferation to support membrane remodelling, energy metabolism and signalling.2830 These observations provide biological context for the associations observed in this study but do not establish a mechanistic role for SCD-1 in RA. Sex-specific differences were observed, with higher palmitoleic acid levels in women with RA. This may reflect interactions between oestrogen, adiposity and SCD-1-mediated lipogenesis. While oestrogen has been reported to repress SCD-1 in some contexts, inflammatory and metabolic alterations in RA, along with higher fat mass in women, may provide substrates or signalling cues that override this repression, promoting increased palmitoleic acid synthesis.31 This sex difference was not observed in controls, highlighting a disease-specific interplay between hormonal and metabolic regulation. However, given the lack of association between palmitoleic acid and disease activity, this finding likely reflects metabolic or hormonal influences rather than direct links to inflammatory burden. Participants with RA also exhibited reduced plasma n-6 PUFAs, including linoleic acid, which was inversely associated with WHR, suggesting a relationship with lower central adiposity. In contrast, arachidonic acid was not associated with disease activity or adiposity in either participants with RA or control participants. Together, these findings suggest that PUFA alterations in RA are not uniform and may reflect differential metabolic utilisation rather than direct relationships with inflammatory burden. Interestingly, higher circulating oleic acid levels were associated with greater RA disease activity. While dietary MUFAs are generally considered protective, elevated endogenously produced MUFAs, driven by SCD-1 activity, may not confer the same benefits. In RA, increased MUFA levels may reflect broader alterations in lipid metabolism related to adiposity or systemic inflammation rather than dietary intake alone. The differential associations observed across fatty acid classes—positive associations of selected MUFAs with disease activity and adiposity, inverse associations of linoleic acid with adiposity and null findings for arachidonic acid—highlight the complexity of fatty acid metabolism in RA and suggest that circulating lipid profiles reflect integrated metabolic and inflammatory processes rather than uniform effects across lipid species. Obesity is common among patients with RA and is linked to worse disease outcomes, including higher disease activity and greater functional disability.32 33 Chronic inflammatory signalling, altered energy demands and adiposity-related hormones (eg, leptin) may further modulate SCD-1 activity, contributing to dysregulated MUFA metabolism.27 34 35 Reduced physical activity is also common in RA and may contribute to increased adiposity and metabolic alterations that influence circulating lipid profiles. Participants with RA also exhibited a less favourable metabolic profile, including elevated triglycerides, lower insulin sensitivity and lower physical activity, which may exacerbate alterations in MUFA metabolism and higher disease activity. The potential biological role of SCD-1 and MUFA metabolism in RA warrants further investigation. Although SCD-1 inhibitors are being explored in metabolic and inflammatory conditions,36 37 the present findings do not establish a causal role for SCD-1 in RA disease activity. Further mechanistic research and longitudinal studies will be needed to determine whether modulation of MUFA metabolism influences inflammatory pathways or clinical outcomes in RA. In controls, plasma oleic acid levels were not associated with age, sex, dietary intake or WHR, supporting the disease-specific nature of these associations. However, the relatively small sample size, particularly within subgroup analyses such as control group and sex-specific comparisons, may have limited the statistical power to detect more subtle associations. Our observation that higher plasma linoleic acid (% of total fatty acids) was negatively associated with WHR in both participants with RA and control participants suggests that circulating linoleic acid may be associated with lower central adiposity after accounting for disease status. This pattern is consistent with epidemiological evidence showing that plasma linoleic acid is inversely associated with adiposity measures, including waist circumference and markers of metabolic dysregulation. For example, in a large cohort of Irish adults, plasma linoleic acid decreased with increasing adiposity and was inversely correlated with markers of inflammation and insulin resistance, indicating a healthier metabolic profile with higher linoleic acid levels.38 Furthermore, plasma and erythrocyte linoleic acid in other cohorts has been associated with lower central adiposity and reduced risk of features of metabolic syndrome.39 These reports are in keeping with our data suggesting that linoleic acid may reflect favourable adiposity and cardiometabolic status rather than simply dietary intake alone. Limitations include the cross-sectional design, which precludes causal inference, and the use of plasma fatty acid measurements, which reflect short-term to medium-term lipid status rather than long-term or tissue-specific metabolism. Potential confounders, including medications, genetic variation or dietary intake not fully captured by self-report may also influence circulating fatty acid levels. Accordingly, differences in plasma fatty acids may reflect both disease-related metabolic alterations and limitations of dietary assessment. Lipid-lowering therapy, as well as RA therapies (eg, biologic agents and corticosteroids) and hormonal factors such as menopause, may also influence lipid metabolism and could contribute to the observed associations. In addition, we did not measure markers of fatty acid oxidation or downstream inflammatory mediators in plasma, which could provide further insight into the functional consequences of altered fatty acid metabolism. This cohort was recruited from academic centres and consisted predominantly of women with established RA, relatively low disease activity and a median BMI in the obese range. Findings should therefore be interpreted in the context of a population with higher adiposity and may not generalise to leaner individuals, men, individuals with early untreated RA or populations with highly active disease or different demographic or treatment distributions. Larger, longitudinal studies are needed to further explore potential subgroup effects by sex, age and treatment status. These findings suggest a model in which selective alterations in MUFA metabolism, rather than global lipid changes, may be associated with disease activity and adiposity in RA, providing a foundation for future mechanistic studies of immunometabolic regulation. Future studies should investigate tissue-specific roles of SCD-1 in immune cells and adipose tissue and determine whether modulation of MUFA metabolism can influence inflammation or clinical outcomes. Integrating metabolic and immunological profiling may provide further insights into personalised RA treatment strategies. Supplementary material